{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etoposide&page=12", "query": { "intervention": "Etoposide", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1002, "total_pages": 101, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etoposide&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etoposide&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T12:42:20.364Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03964090", "title": "Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma" ], "interventions": [ { "name": "TEDD-R", "type": "DRUG" }, { "name": "TEDDI-R", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Isavuconazole", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 48, "start_date": "2019-06-27", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03964090" }, { "nct_id": "NCT01476839", "title": "Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "basiliximab", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "yttrium Y 90-labeled basiliximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2013-02-13", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476839" }, { "nct_id": "NCT00002912", "title": "Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "valspodar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3, "start_date": "1997-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 50, "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 39 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002912" }, { "nct_id": "NCT00002675", "title": "Chemotherapy in Treating Patients With Retinoblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Retinoblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 50, "start_date": "1995-05", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002675" }, { "nct_id": "NCT00088530", "title": "BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "pixantrone, cyclophosphamide, vincristine, rituximab, prednisone", "type": "DRUG" }, { "name": "Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2004-07", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 9, "location_summary": "Fountain Valley, California • Los Angeles, California • Lakeland, Florida + 6 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088530" }, { "nct_id": "NCT00554463", "title": "G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Filgrastim", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2008-01", "completion_date": "2011-08-03", "has_results": true, "last_update_posted_date": "2019-05-29", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 14, "location_summary": "Gainesville, Florida • Miami Beach, Florida • Lexington, Kentucky + 10 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Billings", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00554463" }, { "nct_id": "NCT00602771", "title": "Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "tipifarnib", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 84, "start_date": "2008-01", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2014-10-09", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00602771" }, { "nct_id": "NCT03077828", "title": "Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphocyte-Rich Classical Hodgkin Lymphoma", "Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Recurrent Mixed Cellularity Classical Hodgkin Lymphoma", "Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma", "Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Refractory Mixed Cellularity Classical Hodgkin Lymphoma", "Refractory Nodular Sclerosis Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2017-04-21", "completion_date": "2024-12", "has_results": true, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03077828" }, { "nct_id": "NCT03041311", "title": "Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2017-06-29", "completion_date": "2020-10-29", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 23, "location_summary": "Beverly Hills, California • Fullerton, California • Loma Linda, California + 19 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03041311" }, { "nct_id": "NCT00914849", "title": "Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "AMD3100", "type": "DRUG" }, { "name": "Leukopheresis", "type": "PROCEDURE" }, { "name": "Stem cell transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 68, "start_date": "2009-08", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2017-05-17", "last_synced_at": "2026-10-17T12:42:20.364Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00914849" } ] }